The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter
1
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Purpose: The severity of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) population compared with that in normal glucose tolerance (NGT) individuals has not yet been quantitatively assessed. We investigated the prevalence and the severity of NAFLD in a T2DM population using controlled attenuation parameter (CAP). Materials and Methods: Subjects who underwent testing for biomarkers related to T2DM and CAP using Fibroscan® during a regularhealth check-up were enrolled. CAP values of 250 dB/m and 300 dB/m were selected as the cutoffs for the presence of NAFLD and for moderate to severe NAFLD, respectively. Biomarkers related to T2DM included fasting glucose/insulin, fasting C-peptide, hemoglobin A1c (HbA1c), glycoalbumin, and homeostasis model assessment of insulin resistance of insulin resistance (HOMA-IR). Results: Among 340 study participants (T2DM, n=66; pre-diabetes, n=202; NGT, n=72), the proportion of subjects with NAFLD increased according to the glucose tolerance status (31.9% in NGT; 47.0% in pre-diabetes; 57.6% in T2DM). The median CAP valuewas significantly higher in subjects with T2DM (265 dB/m) than in those with pre-diabetes (245 dB/m) or NGT (231 dB/m) (all p<0.05). Logistic regression analysis showed that subjects with moderate to severe NAFLD had a 2.8-fold (odds ratio) higher risk of having T2DM than those without NAFLD (p=0.02; 95% confidence interval, 1.21–6.64), and positive correlations between the CAP value and HOMA-IR (ρ=0.407) or fasting C-peptide (ρ=0.402) were demonstrated. Conclusion: Subjects with T2DM had a higher prevalence of severe NAFLD than those with NGT. Increased hepatic steatosis was significantly associated with the presence of T2DM, and insulin resistance induced by hepatic fat may be an important mechanisticconnection.
Abstract
Purpose: The severity of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) population compared with that in normal glucose tolerance (NGT) individuals has not yet been quantitatively assessed. We investigated the prevalence and the severity of NAFLD in a T2DM population using controlled attenuation parameter (CAP). Materials and Methods: Subjects who underwent testing for biomarkers related to T2DM and CAP using Fibroscan® during a regularhealth check-up were enrolled. CAP values of 250 dB/m and 300 dB/m were selected as the cutoffs for the presence of NAFLD and for moderate to severe NAFLD, respectively. Biomarkers related to T2DM included fasting glucose/insulin, fasting C-peptide, hemoglobin A1c (HbA1c), glycoalbumin, and homeostasis model assessment of insulin resistance of insulin resistance (HOMA-IR). Results: Among 340 study participants (T2DM, n=66; pre-diabetes, n=202; NGT, n=72), the proportion of subjects with NAFLD increased according to the glucose tolerance status (31.9% in NGT; 47.0% in pre-diabetes; 57.6% in T2DM). The median CAP valuewas significantly higher in subjects with T2DM (265 dB/m) than in those with pre-diabetes (245 dB/m) or NGT (231 dB/m) (all p<0.05). Logistic regression analysis showed that subjects with moderate to severe NAFLD had a 2.8-fold (odds ratio) higher risk of having T2DM than those without NAFLD (p=0.02; 95% confidence interval, 1.21–6.64), and positive correlations between the CAP value and HOMA-IR (ρ=0.407) or fasting C-peptide (ρ=0.402) were demonstrated. Conclusion: Subjects with T2DM had a higher prevalence of severe NAFLD than those with NGT. Increased hepatic steatosis was significantly associated with the presence of T2DM, and insulin resistance induced by hepatic fat may be an important mechanisticconnection.
참고문헌 (31)
- Marchesini G, "Nonalcoholic fatty liver disease: a feature of the metabolic syndrome", Diabetes, 50, pp.1844~1850 (2001)
- Angulo P, "Nonalcoholic fatty liver disease", N Engl J Med, 346, pp.1221~1231 (2002)
- Kojima S, "Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background", J Gastroenterol, 38, pp.954~961 (2003)
- Browning JD, "Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity", Hepatology, 40, pp.1387~1395 (2004)
- 김현창, "Normal Serum Aminotransferase Levels and the Metabolic Syndrome: Korean National Health and Nutrition Examination Surveys", Yonsei Medical Journal, 47(4), pp.542~550 (2006), 연세대학교의과대학
- Moore JB, "Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome", Proc Nutr Soc, 69, pp.211~220 (2010)
- Kotronen A, "Fatty liver: a novel component of the metabolic syndrome", Arterioscler Thromb Vasc Biol, 28, pp.27~38 (2008)
- Sanyal AJ, "AGA technical review on nonalcoholic fatty liver disease", Gastroenterology, 123, pp.1705~1725 (2002)
- Jinmi Lee, "GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease", Diabetes & Metabolism Journal, 36(4), pp.262~ (2012), Korean Diabetes Association (KAMJE)[DOI]
- Kim HJ, "Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults", Arch Intern Med, 164, pp.2169~2175 (2004)
- Anstee QM, "Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis", Nat Rev Gastroenterol Hepatol, 10, pp.330~344 (2013)
- Park SK, "Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study", Hepatology, 57, pp.1378~1383 (2013)
- Bae JC, "Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study", Diabetes Care, 34, pp.727~729 (2011)
- Shibata M, "Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men", Diabetes Care, 30, pp.2940~2944 (2007)
- Saadeh S, "The utility of radiological imaging in nonalcoholic fatty liver disease", Gastroenterology, 123, pp.745~750 (2002)
- Sasso M, "Controlled attenuation parameter (CAP): a novel VCTETM guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes", Ultrasound Med Biol, 36, pp.1825~1835 (2010)
- Myers RP, "Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography", Liver Int, 32, pp.902~910 (2012)
- Sasso M, "Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(® ): validation in chronic hepatitis C", J Viral Hepat, 19, pp.244~253 (2012)
- Kumar M, "Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance?", J Gastroenterol Hepatol, 28, pp.1194~1201 (2013)
- Chon YE, "Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population", Liver Int, 34, pp.102~109 (2014)
- American Diabetes Association, "Standards of medical care in diabetes--2012", Diabetes Care, 35(Suppl 1), pp.S11~S63 (2012)
- Saverymuttu SH, "Ultrasound scanning in the detection of hepatic fibrosis and steatosis", Br Med J (Clin Res Ed), 292, pp.13~15 (1986)
- Castera L, "Non-invasive evaluation of liver fibrosis using transient elastography", J Hepatol, 48, pp.835~847 (2008)
- Jimba S, "Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults", Diabet Med, 22, pp.1141~1145 (2005)
- Adams LA, "Nonalcoholic fatty liver disease", Ann Epidemiol, 17, pp.863~869 (2007)
- de Lédinghen V, "Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations", J Hepatol, 60, pp.1026~1031 (2014)
- Barma P, "Lipid induced overexpression of NF-kappaB in skeletal muscle cells is linked to insulin resistance", Biochim Biophys Acta, 1792, pp.190~200 (2009)
- Seppälä-Lindroos A, "Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men", J Clin Endocrinol Metab, 87, pp.3023~3028 (2002)
- Bugianesi E, "Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms", Diabetologia, 48, pp.634~642 (2005)
- Kiesewetter CH, "Hepatic changes in the failing Fontan circulation", Heart, 93, pp.579~584 (2007)
- Ja Young Jeon, "Prevalence of Diabetes and Prediabetes according to Fasting Plasma Glucose and HbA1c", Diabetes & Metabolism Journal, 37(5), pp.349~ (2013), Korean Diabetes Association (KAMJE)[DOI]